182 related articles for article (PubMed ID: 28445481)
61. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
62. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
[TBL] [Abstract][Full Text] [Related]
63. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
64. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
65. IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
Buoncervello M; Romagnoli G; Buccarelli M; Fragale A; Toschi E; Parlato S; Lucchetti D; Macchia D; Spada M; Canini I; Sanchez M; Falchi M; Musella M; Biffoni M; Belardelli F; Capone I; Sgambato A; Vitiani LR; Gabriele L
Oncotarget; 2016 May; 7(18):26361-73. PubMed ID: 27028869
[TBL] [Abstract][Full Text] [Related]
66. Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Fenouille N; Grosso S; Yunchao S; Mary D; Pontier-Bres R; Imbert V; Czerucka D; Caroli-Bosc FX; Peyron JF; Lagadec P
J Pathol; 2012 May; 227(1):118-29. PubMed ID: 22069124
[TBL] [Abstract][Full Text] [Related]
67. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
[TBL] [Abstract][Full Text] [Related]
68. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Kontek R; Nowicka H
Drug Chem Toxicol; 2013 Jul; 36(3):335-42. PubMed ID: 23126525
[TBL] [Abstract][Full Text] [Related]
69. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
70. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
[TBL] [Abstract][Full Text] [Related]
71. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
72. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
73. Current status of second-line therapy for metastatic colorectal cancer.
Rothenberg ML
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
[TBL] [Abstract][Full Text] [Related]
74. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
Arcaroli JJ; Powell RW; Varella-Garcia M; McManus M; Tan AC; Quackenbush KS; Pitts TM; Gao D; Spreafico A; Dasari A; Touban BM; Messersmith WA
Mol Oncol; 2012 Jun; 6(3):370-81. PubMed ID: 22521243
[TBL] [Abstract][Full Text] [Related]
75. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.
Du GJ; Wang CZ; Zhang ZY; Wen XD; Somogyi J; Calway T; He TC; Du W; Yuan CS
J Pharm Pharmacol; 2012 May; 64(5):727-34. PubMed ID: 22471369
[TBL] [Abstract][Full Text] [Related]
76. A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Weiswald LB; Richon S; Massonnet G; Guinebretière JM; Vacher S; Laurendeau I; Cottu P; Marangoni E; Nemati F; Validire P; Bellet D; Bièche I; Dangles-Marie V
Br J Cancer; 2013 Apr; 108(8):1720-31. PubMed ID: 23538387
[TBL] [Abstract][Full Text] [Related]
77. Cytotoxic properties of unfractionated and fractionated bromelain alone or in combination with chemotherapeutic agents in colorectal cancer cells.
Tsai KY; Wei PL; Azarkan M; M'Rabet N; Makondi PT; Chen HA; Huang CY; Chang YJ
PLoS One; 2023; 18(6):e0285970. PubMed ID: 37262048
[TBL] [Abstract][Full Text] [Related]
78. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.
Dylla SJ; Beviglia L; Park IK; Chartier C; Raval J; Ngan L; Pickell K; Aguilar J; Lazetic S; Smith-Berdan S; Clarke MF; Hoey T; Lewicki J; Gurney AL
PLoS One; 2008 Jun; 3(6):e2428. PubMed ID: 18560594
[TBL] [Abstract][Full Text] [Related]
79. S-Adenosylmethionine Treatment of Colorectal Cancer Cell Lines Alters DNA Methylation, DNA Repair and Tumor Progression-Related Gene Expression.
Zsigrai S; Kalmár A; Nagy ZB; Barták BK; Valcz G; Szigeti KA; Galamb O; Dankó T; Sebestyén A; Barna G; Szabó V; Pipek O; Medgyes-Horváth A; Csabai I; Tulassay Z; Igaz P; Takács I; Molnár B
Cells; 2020 Aug; 9(8):. PubMed ID: 32784836
[TBL] [Abstract][Full Text] [Related]
80. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy.
Zheng DW; Dong X; Pan P; Chen KW; Fan JX; Cheng SX; Zhang XZ
Nat Biomed Eng; 2019 Sep; 3(9):717-728. PubMed ID: 31332342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
